{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:43:32Z","timestamp":1792017812154,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["4D Nanoscope"],"award-info":[{"award-number":["4D Nanoscope"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1181"],"award-info":[{"award-number":["CRC1181"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>C-reactive protein (CRP) is often normal in patients with psoriatic disease. Herein, we aimed to define markers of systemic inflammation in patients with monomorphic and polymorphic psoriatic skin, entheseal, and joint disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Three-step approach: (i) selection of serum markers elevated in psoriatic arthritis compared healthy controls from a panel of 10 different markers reflecting the pathophysiology of psoriatic disease; (ii) testing of these selected markers as well as C-reactive protein (CRP) in a larger cohort of 210 individuals- 105 healthy controls and 105 patients with psoriatic disease with either monomorphic skin (S), entheseal (E) or joint (A) involvement or polymorphic disease with various combinations of skin, entheseal and joint disease (SE, SA, EA, SEA); (iii) testing whether tumor necrosis factor (TNF) and interleukin (IL)-17 inhibitor therapy normalizes these markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CRP was not elevated or was rarely elevated in the subgroups (S 0%, E 0%, A 20%, SE 7%, SA 33%, EA 27%, SEA 33%) despite active psoriatic disease. In sharp contrast, beta-defensin 2 and lipocalin-2 levels were elevated in the majority of patients with monomorphic skin (93% and 73%) and entheseal (both 53%), but not joint disease (27% and 20%). Conversely, elevations of calprotectin and IL-8 were found in the majority of patients with monomorphic joint disease (both 73%). IL-22 was elevated in all three monomorphic disease manifestations (S 60%, E 46%; A 60%). Furthermore, the vast majority of patients with polymorphic psoriatic disease (SE, SA, EA, SEA) showed widespread marker elevation. IL-17- and TNF inhibitor treatment significantly lowered all 5 markers of inflammation in PsA patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Systemic inflammation is detectable in the majority of patients with psoriatic disease, even if CRP is normal. The respective marker pattern depends on the manifestation of psoriatic disease with respect to skin, entheseal, and joint involvement.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13075-020-2111-8","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T16:07:16Z","timestamp":1581523636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations"],"prefix":"10.1186","volume":"22","author":[{"given":"Maria V.","family":"Sokolova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Nas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario M.","family":"Zaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"issue":"10","key":"2111_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):2095\u20136.","journal-title":"N Engl J Med"},{"issue":"5","key":"2111_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4103\/2229-5178.164483","volume":"6","author":"AR Vadakayil","year":"2015","unstructured":"Vadakayil AR, Dandekeri S, Kambil SM, Ali NM. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J. 2015;6(5):322\u20135.","journal-title":"Indian Dermatol Online J"},{"issue":"9","key":"2111_CR3","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/art.39700","volume":"68","author":"PJ Mease","year":"2016","unstructured":"Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic aryhritis. Arthritis Rheumatol. 2016;68(9):2163\u201373.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 2","key":"2111_CR4","doi-asserted-by":"publisher","first-page":"ii104","DOI":"10.1136\/annrheumdis-2012-203037","volume":"72","author":"F Villanova","year":"2013","unstructured":"Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013;72(Suppl 2):ii104\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2111_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3899\/jrheum.111240","volume":"39","author":"CT Ritchlin","year":"2012","unstructured":"Ritchlin CT. Strategies for biomarker development in psoriatic disease: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39(2):423\u20136.","journal-title":"J Rheumatol"},{"issue":"8","key":"2111_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3899\/jrheum.130462","volume":"40","author":"O FitzGerald","year":"2013","unstructured":"FitzGerald O, Mease PJ. Biomarkers: project update from the GRAPPA 2012 annual meeting. J Rheumatol. 2013;40(8):1453\u20134.","journal-title":"J Rheumatol"},{"issue":"4","key":"2111_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1208\/s12248-017-0094-4","volume":"19","author":"C Soderstrom","year":"2017","unstructured":"Soderstrom C, Berstein G, Zhang W, Valdez H, Fitz L, Kuhn M, Fraser S. Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serumand skin. AAPS J. 2017;19(4):1218\u201322.","journal-title":"AAPS J"},{"issue":"10","key":"2111_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/art.40921","volume":"71","author":"S Siebert","year":"2019","unstructured":"Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ. Responsiveness of serum C- reactive protein, interleukin- 17A, and interleukin- 17F levels to Ustekinumab in psoriatic arthritis: lessons from two phase III, multicenter, double- blind, Placebo- Controlled Trials. Arthritis Rheumatol. 2019;71(10):1660\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"330","key":"2111_CR9","doi-asserted-by":"publisher","first-page":"330ra37","DOI":"10.1126\/scitranslmed.aad8996","volume":"8","author":"\u00d6 Ulu\u00e7kan","year":"2016","unstructured":"Ulu\u00e7kan \u00d6, Jimenez M, Karbach S, et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med. 2016;8(330):330ra37.","journal-title":"Sci Transl Med"},{"key":"2111_CR10","doi-asserted-by":"publisher","first-page":"467541","DOI":"10.1155\/2014\/467541","volume":"2014","author":"A Kyriakou","year":"2014","unstructured":"Kyriakou A, Patsatsi A, Vyzantiadis TA, Sotiriadis D. Serum levels of TNF-\u03b1, IL-12\/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J Immunol Res. 2014;2014:467541.","journal-title":"J Immunol Res"},{"key":"2111_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/MI.2005.273","volume":"2005","author":"O Arican","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-a, IFN-c, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat Inflamm. 2005;2005:273\u20139.","journal-title":"Mediat Inflamm"},{"issue":"3","key":"2111_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","volume":"139","author":"F Kolbinger","year":"2017","unstructured":"Kolbinger F, Loesche C, Valentin MA, et al. \u03b2-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139(3):923\u201332.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2111_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00403-012-1306-5","volume":"305","author":"J Roman\u00ed","year":"2013","unstructured":"Roman\u00ed J, Caix\u00e0s A, Ceperuelo-Mallafr\u00e9 V, et al. Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch Dermatol Res. 2013;305(2):105\u201312.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"2111_CR14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/1346-8138.12248","volume":"40","author":"T Shimauchi","year":"2013","unstructured":"Shimauchi T, Hirakawa S, Suzuki T, et al. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. J Dermatol. 2013;40(10):805\u201312.","journal-title":"J Dermatol"},{"issue":"3","key":"2111_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jdermsci.2010.03.018","volume":"58","author":"YH Lo","year":"2010","unstructured":"Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci. 2010;58(3):225\u20137.","journal-title":"J Dermatol Sci"},{"issue":"6","key":"2111_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1155\/2013\/856056","volume":"35","author":"A Michalak-Stoma","year":"2013","unstructured":"Michalak-Stoma A, Bartosi\u0144ska J, Kowal M, Juszkiewicz-Borowiec M, Gerkowicz A, Chodorowska G. Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers. 2013;35(6):625\u201331.","journal-title":"Dis Markers"},{"key":"2111_CR17","first-page":"696415","volume":"2014","author":"C Hannson","year":"2014","unstructured":"Hannson C, Eriksson C, Alenius GM. S-calprotectin (S100A8\/S100A9): a potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res. 2014;2014:696415.","journal-title":"J Immunol Res"},{"key":"2111_CR18","doi-asserted-by":"publisher","first-page":"268257","DOI":"10.1155\/2014\/268257","volume":"2014","author":"YJ Hwang","year":"2014","unstructured":"Hwang YJ, Jung HJ, Kim MJ, et al. Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis. Mediat Inflamm. 2014;2014:268257.","journal-title":"Mediat Inflamm"},{"issue":"3","key":"2111_CR19","first-page":"415","volume":"18","author":"V Bevelacqua","year":"2006","unstructured":"Bevelacqua V, Libra M, Mazzarino MC, et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med. 2006;18(3):415\u201323.","journal-title":"Int J Mol Med"},{"key":"2111_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/annrheumdis-2018-214737","volume":"78","author":"V Chandran","year":"2019","unstructured":"Chandran V, Abji F, Perruccio AV, Gandhi R, Li S, Cook RJ, Gladman DD. Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. Ann Rheum Dis. 2019;78:796\u2013801.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2111_CR21","doi-asserted-by":"publisher","first-page":"R148","DOI":"10.1186\/ar3090","volume":"12","author":"U Fiocco","year":"2010","unstructured":"Fiocco U, Sfriso P, Oliviero F, et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-\u03b1 blockade in the knee joint. Arthritis Res Ther. 2010;12(4):R148.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2111_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1346-8138.2010.01018.x","volume":"38","author":"MF Abdel-Hamid","year":"2011","unstructured":"Abdel-Hamid MF, Aly DG, Saad NE, Emam HM, Ayoub DF. Serum levels of interleukin-8, tumor necrosis factor-\u03b1 and \u03b3-interferon in Egyptian psoriatic patients and correlation with disease severity. J Dermatol. 2011;38(5):442\u20136.","journal-title":"J Dermatol"},{"issue":"5","key":"2111_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/MI.2005.273","volume":"2005","author":"O Arican","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat Inflamm. 2005;2005(5):273\u20139.","journal-title":"Mediat Inflamm"},{"issue":"12","key":"2111_CR24","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1002\/art.38822","volume":"66","author":"M Biniecka","year":"2014","unstructured":"Biniecka M, Connolly M, Gao W, et al. Redox-mediated angiogenesis in the hypoxic joint of inflammatory arthritis. Arthritis Rheumatol. 2014;66(12):3300\u201310.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"2111_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.joca.2019.01.019","volume":"27","author":"A Berlin","year":"2019","unstructured":"Berlin A, Simon D, Tascilar K, et al. The ageing joint-standard age- and sex-related values of bone erosions and osteophytes in the hand joints of healthy individuals. Osteoarthr Cartil. 2019;27(7):1043\u20137.","journal-title":"Osteoarthr Cartil"},{"issue":"7","key":"2111_CR26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/rheumatology\/keq105","volume":"49","author":"V Chandran","year":"2010","unstructured":"Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford). 2010;49(7):1399\u2013405.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2111_CR27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3899\/jrheum.121162","volume":"40","author":"V Chandran","year":"2013","unstructured":"Chandran V, Shen H, Pollock RA, Pellett FJ, Carty A, Cook RJ, Gladman DD. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J Rheumatol. 2013;40(6):866\u201371.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2111-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-2111-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2111-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T14:21:39Z","timestamp":1722435699000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-2111-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2111"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-2111-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"4 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided written informed consent and the institutional review board (IRB)\/ethics committee (Ethik-Kommission der Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg) approved the analysis of proteins in stored serum samples for the patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}